Fragment 176-191 & CJC-1295 & Ipamorelin Peptide Blend
Researchers have suggested that growth hormone-releasing peptides (GHRPs), growth hormone secretagogues (GSHs), and analogs of growth hormones (hGH) may exhibit potential to promote growth hormone secretion. When taken together, they may exert beneficial actions on an organism. These include increased fat metabolism, increased lean mass, better sleep cycle, and good intestinal and cardiac functioning. CJC-1295 is a synthetic peptide composed of 29 amino acids analogous to the growth hormone hGH. Ipamorelin is a synthetic pentapeptide and has been categorized by scientists as one of the growth hormone secretagogues (GSH). Fragment 176-191 peptide, as the name suggests, is a small ‘fragment’ of the growth hormone hGH composed of 15 amino acids. Taken together, this blend may help trigger a small portion of the pituitary gland, possibly stimulating the release of growth hormones. This blend appears to help regulate growth hormone concentration and maintain equilibrium levels.
Chemical Makeup(1) (2) (3)
Fragment 176-191: C78H125N23O23S2
CJC-1295: 3367.9 g/mol
Ipamorelin: 711.9 g/mol
Fragment 176-191: 1817.12 g/mol
Other known titles
- CJC-1295 with DAC
- CJC-1295 without DAC
Both forms of CJC-1295 peptide appear to essentially exert the same action; however, the addition of DAC (known as the drug affinity complex) may significantly change the duration of the action of the peptide. CJC-1295 with DAC may have longer-lasting action than CJC-1295 without DAC.
- Ipamorelin Acetate
- AOD 9604
- GH (hGH) lipolytic fragment
- Somatostatin (177-191), tyrosyl
Research and Clinical Studies
Fragment 176-191 & CJC-1295 & Ipamorelin Blend, and Growth Hormones
Test subjects aged between 20 and 40 were enrolled in a clinical trial.(4) All subjects were divided into two groups – one was presented with a saline placebo and the rest with the peptide. A blood sample was collected from all subjects before and after the peptide presentation. After completion of the study, it was reported by the researchers that the peptide group appeared to exhibit a 7.5-fold increase in their growth hormone levels compared to the standard group. The trend suggested that these hormones increased gradually throughout the study and remained unchanged for at least 7 days after discontinuing presentation. Another study(5) was conducted on male test subjects aged between 20 and 60. Similar to the previous study, these subjects were also divided into two groups – one was presented with a placebo while the rest were given the peptide. The peptide group was given gradually increasing concentrations of the compound during the study. Upon analyzing the blood samples collected from these subjects, it was observed that there appeared to be a concentration-dependent increase, of up to 10 times, in the concentration of growth hormones among the peptide subjects. As per Madalina Ionescu et al., “The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may benefit patients with intact pituitary GH secretory capability.”(4)
From the year 2000 onwards, there have been numerous studies conducted on test models exhibiting growth hormone deficiency. The results so far have posited that these peptides have either of the two mechanisms of action:
- Potential ability to stimulate the pituitary gland to release growth hormones, or
- Potential ability to act on the arcuate nucleus of the hypothalamus (6)
In a clinical study focused on young test subjects, six growth hormone deficient subjects were enrolled(7) for eight months and were presented with various concentrations of growth hormone release stimulating peptides. All subjects were diligently monitored throughout the study for any increased growth hormone secretion. After the completion of the study, it was reported by the researchers that there appeared to be a gradual, constant increase in the levels of growth hormones in all the subjects, even after discontinuing peptide. As per V Mericq et al., the studies suggested that the peptides were “well tolerated and can stimulate GH secretion.”
Fragment 176-191 & CJC-1295 & Ipamorelin Blend, and General Research
As part of one clinical study,(8) numerous test subjects were subjected to growth hormone secretagogues and growth hormone-releasing peptides in order to study the potential of these peptides. All these subjects were monitored for any physiological changes. After completing this study, it was noted that there appeared to be a significant improvement in the growth rate of all subjects. It may have also led to increased hunger, improved lean mass, improved sleep cycle in all test models, possibly also reducing bone turnover in obese subjects. The study report states these peptides “increase lean body mass, reduces fat mass, increases exercise tolerance and maximum oxygen uptake, enhances muscle strength, and improves linear growth.”
Fragment 176-191 & CJC-1295 & Ipamorelin Blend, and Lipolytic Action
A clinical trial(9) was conducted in 2004 to study the peptide’s potential lipolytic (fat-burning) action. 300 test subjects were enrolled in this study were all presented with the Fragment 176-191 peptide for 12 weeks. These subjects were divided into 6 groups – one given a saline placebo, and the rest presented with different peptide concentrations. The group presented with minimal peptide presence appeared to exhibit a notable reduction in their body weight (up to 2.8 kilograms). These peptides may have also helped improve these subjects’ cholesterol profiles and glucose tolerance levels. The research team stated, “The evidence from the trial is that over 12 weeks, [the peptide] induces competitive weight loss with accompanying health benefits…”
Fragment 176-191 & CJC-1295 & Ipamorelin Blend, and Regeneration
Thirty-two experimental rabbits were examined as part of this 2015 study,(10) all of whom were divided into four groups of eight. All four groups were presented with placebo, Fragment 176-191 peptide, hyaluronic acid, or a combination of the peptide ad hyaluronic acid for about 7 weeks. After the completion of the study, all rabbits were checked for any signs of cartilage damage. Among all groups, the rabbits presented with peptide and hyaluronic acid combination appeared to show minimal cartilage degeneration. These results suggest that the peptide may have the capability to enhance cartilage regeneration and repair. The report concluded that “Intra-articular AOD9604 using ultrasound guidance enhanced cartilage regeneration, and combined AOD9604 and HA were more effective than HA or AOD9604 alone in the collagenase-induced knee OA rabbit model.” (10)
Fragment 176-191 & CJC-1295 & Ipamorelin Blend, and Sleep Cycle
Studies(8) have indicated that the number of growth hormones secreted in an organism may possibly influence the deep non-REM sleep cycle (NREMS). Introducing the peptide blend of Fragment 176-191, Ipamorelin, and CJC 1295 may help improve the sleep cycle, as these peptides are believed to increase growth hormone secretion.
Fragment 176-191 & CJC-1295 & Ipamorelin Peptide Blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
- National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC
- National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin
- National Center for Biotechnology Information (2023). PubChem Substance Record for SID 319360420, 386264-39-7, Source: ToxPlanet. https://pubchem.ncbi.nlm.nih.gov/substance/319360420
- Ionescu M, Frohman LA. Pulsatile growth hormone secretion (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694.
- Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60. https://pubmed.ncbi.nlm.nih.gov/9661608/
- Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
- News, Medical and Life Sciences, Obesity drug codenamed AOD 9604 highly successful in trials, 16 December 2004, https://www.news-medical.net/news/2004/12/16/6878.aspx
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694. https://pubmed.ncbi.nlm.nih.gov/26275694/
- Obal F Jr, Krueger JM. GHRH and sleep. Sleep Med Rev. 2004 Oct;8(5):367-77. doi: 10.1016/j.smrv.2004.03.005. PMID: 15336237. https://pubmed.ncbi.nlm.nih.gov/15336237/
NOTE: These products are intended for laboratory research use only. Fragment 176-191 & CJC-1295 & Ipamorelin Blend for sale (12mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.